155 filings
ARS
2023 FY
KZR
Kezar Life Sciences Inc
26 Apr 24
Annual report to shareholders
4:12pm
DEFA14A
KZR
Kezar Life Sciences Inc
26 Apr 24
Additional proxy soliciting materials
4:10pm
DEF 14A
KZR
Kezar Life Sciences Inc
Definitive proxy
26 Apr 24
4:06pm
PRE 14A
KZR
Kezar Life Sciences Inc
Preliminary proxy
16 Apr 24
4:18pm
424B5
KZR
Kezar Life Sciences Inc
22 Mar 24
Prospectus supplement for primary offering
4:05pm
S-8
j4h9s9aj
14 Mar 24
Registration of securities for employees
4:33pm
8-K
ua1g6yoy
14 Mar 24
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
4:04pm
8-K
1nyfrl
8 Jan 24
Results of Operations and Financial Condition
8:36am
8-K
vz1 j5dzpoo
4 Dec 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:28pm
8-K
lp9qhtip 9qmhc3tuz15
13 Nov 23
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
12:00am
8-K
4x5ki1pa
27 Oct 23
Departure of Directors or Certain Officers
4:06pm
8-K
ui6wyextp78
3 Oct 23
Cash runway extended to fund PALIZADE global Phase 2b clinical trial evaluating zetomipzomib in lupus nephritis; topline data expected mid-2026
4:14pm
8-K
xlb dfsbpj23tkext
20 Sep 23
Entry into a Material Definitive Agreement
6:40pm
8-K
3pkf2ii32p2
11 Aug 23
Other Events
5:52pm
8-K
njvnimz
10 Aug 23
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
4:06pm
8-K
hyll5dn16sx46
26 Jul 23
Departure of Directors or Certain Officers
4:37pm
8-K
b9z2epev
16 Jun 23
Material Modifications to Rights of Security Holders
4:07pm